LILRB4/CD85k/ILT3 Protein, Human (HEK293, His)

The LILRB4/CD85k/ILT3 protein is a key inhibitory receptor that plays a key role in immune regulation and tolerance. As a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, it inhibits receptor-mediated phosphorylation, intracellular calcium mobilization, and FCGR1A/CD64-mediated monocyte activation, thereby reducing TNF production. LILRB4/CD85k/ILT3 Protein, Human (HEK293, His) is the recombinant human-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293 , with C-6*His labeled tag.

LILRB4/CD85k/ILT3, an inhibitory receptor, plays a pivotal role in immune regulation and the establishment of immune tolerance. Functioning as a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, this protein is involved in diverse cellular processes. It inhibits receptor-mediated phosphorylation of cellular proteins and the mobilization of intracellular calcium ions, and it further down-regulates FCGR1A/CD64-mediated monocyte activation, leading to reduced TNF production. Additionally, LILRB4/ILT3 impedes T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells, and promoting the generation of CD8+ T suppressor cells. It induces the up-regulation of CD86 on dendritic cells and interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. The inhibitory effects are at least partially mediated through interactions with FN1 and the phosphatase PTPN6.

Loaded Recombinant Human LILRB4 (C-6His) on Pro-A Biosensor, can bind Recombinant Human LGALS8 with an affinity constant of 0.1-0.5 μM as determined in BLI assay.

Human

HEK293

C-6*His

Q8NHJ6-1 (Q22-E259)

11006  [NCBI]

Extracellular Domain

QAGPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEPKNKARFSIPSMTEDYAGRYRCYYRSPVGWSQPSDPLELVMTGAYSKPTLSALPSPLVTSGKSVTLLCQSRSPMDTFLLIKERAAHPLLHLRSEHGAQQHQAEFPMSPVTSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVSGSLEDPRPSPTRSVSTAAGPEDQPLMPTGSVPHSGLRRHWE

Approximately 37 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of 20 mM His-HCl, 15% trehalose, 4% mannitol, 0.05% Tween 80, pH 6.0.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.